Boston Scientific WATCHMAN FLX Stroke Risk Reduction

What happened: On March 29, 2026, Boston Scientific (BSX) announced that its CHAMPION-AF trial met all primary and secondary safety and efficacy endpoints for the WATCHMAN FLX device, a left atrial appendage closure (LAAC) device used to reduce stroke risk in patients with atrial fibrillation. The trial compared the WATCHMAN FLX to non-vitamin K antagonist oral anticoagulants (NOACs). Leerink analyst Mike Kratky reiterated his 'Outperform' rating on BSX, citing the positive results. However, BSX's Q1 2026 earnings call revealed reduced full-year organic growth guidance to 6.5%-8% due to headwinds in the EP, WATCHMAN, and Urology business units.

Market impact: The positive CHAMPION-AF trial results boosted investor confidence in BSX, with the stock being named one of the 8 most oversold strong buy-rated stocks and one of the 10 best 52-week low NYSE stocks to buy. The WATCHMAN FLX device's proven efficacy in stroke risk reduction may drive demand for the product, benefiting BSX's revenue. Conversely, the reduced growth guidance may impact investor sentiment and valuation repricing for BSX and other players in the atrial fibrillation and stroke prevention markets, such as Abbott Laboratories (ABT) and Medtronic (MDT).

What to watch next: Investors should monitor BSX's upcoming Q2 2026 earnings call (scheduled for May 2026) for further details on the WATCHMAN FLX commercial launch and the impact of the reduced growth guidance on the company's financial outlook. Additionally, the FDA's decision on the WATCHMAN FLX device's Premarket Approval (PMA) application, expected in Q3 2026, will be a crucial catalyst for BSX and the broader LAAC market.